-+ 0.00%
-+ 0.00%
-+ 0.00%

BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million

PUBT·08/11/2026 11:04:23
Listen to the news
BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million
  • BioXcel Therapeutics entered a 12th amendment to its April 19, 2022 credit agreement with lenders led by administrative agent Oaktree Fund Administration.
  • Deadline extended to Aug. 21, 2026 to sign a lender-acceptable deal to repay all obligations or secure an alternative capital solutions transaction.
  • Minimum liquidity covenant cut to $3 million from $6.25 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-093710), on August 11, 2026, and is solely responsible for the information contained therein.